Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (ISCOAT)

Lancet

Volumn 348, Issue 9025, 1996, Pages 423-428

  Palareti, Gualtiero ^a   Leali, Nicoletta ^a   Coccheri, Sergio ^a   Poggi, Mario ^a   Manotti, Cesare ^b   D'Angelo, Armando ^c   Pengo, Vittorio ^d   Erba, Nicoletta ^e   Moia, Marco ^f   Ciavarella, Nicola ^g   Devoto, Gianluigi ^h   Berrettini, Mauro ⁱ   Musolesi, Serena ^j  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Ospedale Regionale   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

^e Ospedale di Merate   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

^g POLICLINICO   (Italy)

^h Ospedale di Lavagna   (Italy)

ⁱ UNIVERSITY OF PERUGIA   (Italy)

^j UNIVERSITY OF BOLOGNA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; WARFARIN;

ADULT; AGE; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR DISEASE; DRUG MONITORING; FEMALE; FOLLOW UP; HEART DISEASE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; THROMBOEMBOLISM;

EID: 15844427401     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)01109-9     Document Type: Article

References (29)

1. Hirsh J. Drug Therapy: oral anticoagulant drugs. N Engl J Med 1991; 324: 1865-75.
2. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding-clinical epidemiology, prediction, and prevention. Am J Med 1993; 95: 315-28.
3. Levine MN, Hirsh J, Landefeld CS, Raskob G. Haemorrhagic complications of anticoagulant treatment. Chest 1992; 102: 352s-63s.
4. van der Meer FJM, Rosendaal FR, Vandenbroucke JP, Briet E. Bleeding complications in oral anticoagulant therapy-an analysis of risk factors. Arch Intern Med 1993; 153: 1557-62.
5. WHO Expert Committee On Biological Standardization, 33rd Report. Geneva: WHO. Tech Rep Ser 1983; 687: 81-105.
6. Loeliger EA. ICSH/ICTH recommendations for reporting prothrombin time in oral anticoagulant control. Thromb Haemost 1985; 53: 155-56.
7. Fihn SD, McDonell M, Martin D, et al. Risk factors for complications of chronic anticoagulation: a multicentre study. Ann Intern Med 1993; 118: 511-20.
8. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989; 87: 144-52.
9. Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995; 332: 1661-65.
10. Mariani G, Manotti C, Dettori AG. A computerized regulation of dosage in oral anticoagulant therapy. Res Clin Lab 1990; 20: 119-25.
11. Rosendaal FR, Cannegieter SC, Vandermeer FJM, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-7.
12. Bussey H, Respond R, Quandt C, Clark GM. The safety and effectiveness of long-term warfarin therapy in an anticoagulation clinic. Pharmacotherapy 1989; 9: 214-9.
13. Petty G, Lennihan L, Mohr J, et al. Complications of long-term anticoagulation. Ann Neurol 1988; 23: 570-04.
14. Petitti DB, Strom BL, Melmon KL. Duration of warfarin anticoagulant therapy and the probabilities of recurrent thromboembolism and haemorrhage. Am J Med 1986; 81: 255-59.
15. Gurwitz JH, Goldberg RJ, Holden A, Knapic N, Ansell J. Age related risks of long-term oral anticoagulant therapy. Arch Intern Med 1988; 148: 1733-36.
16. Launbjerg J, Egeblad H, Heaf J, Nielsen NH, Fugleholm AM, Ladefoged K. Bleeding complications to oral anticoagulant therapy: muItivariate analysis of 1010 treatment years in 551 outpatients. J Intern Med 1991; 229: 351-55.
17. Gitter MJ, Jaeger TM, Petterson TM, Gersh BJ, Phil D, Silverstein MD. Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota. Mayo Clin Proc 1995; 70: 725-33.
18. Palareti G, Coccheri S, Poggi M, et al. Oral anticoagulant therapy control: evidence that INR expression improves the inter-laboratory comparability of results: the Bologna oral anticoagulant control exercise. Thromb Haemost 1987; 58: 905-10.
19. Hirsh J. Is the dose of warfarin prescribed by American physicians unnecessarily high? Arch Intern Med 1987; 147: 769-71.
20. Hirsh J, Dalen JE, Deykin D, Poller L. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1992; 102: S312-26.
21. Jaffin BW, Bliss CM, Lamont JT. Significance of occult gastrointestinal bleeding during anticoagulation therapy. Am J Med 1987; 83: 269-72.
22. Petitti DB, Strom BL, Melmon KL. Prothrombin time ratio and other factors associated with bleeding in patients treated with warfarin. J Clin Epidemiol 1989; 42: 759-64.
23. Beyth RJ, Landefeld CS. Anticoagulants in older patients: a safety perspective. Drugs Aging 1995; 6: 45-54.
24. Scott PJW. Anticoagulant drugs in the elderly: the risks usually outweigh the benefits. BMJ 1988; 2: 1261-63.
25. Kutner M, Nixon G, Silverstone F. Physicians' attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation. Arch Intern Med 1991; 151: 1950-53.
26. Forfar JC. A 7-year analysis of hemorrhage in patients on long-term anticoagulant treatment. Br Heart J 1979; 42: 128-32.
27. Lundstrom T, Ryden L. Hemorrhagic and thromboembolic complications in patients with atrial fibrillation on anticoagulant prophylaxis. J Intern Med 1989; 225: 137-42.
28. Levine MN, Hirsh J. Hemorrhagic complications of long-term anticoagulant therapy for ischemic cerebral vascular disease. Stroke 1986; 17: 111-16.
29. Dahl T, Abildgaard U, Sandset PM. Long-term anticoagulant therapy in cerebrovascular disease: does bleeding outweigh the benefit? J Intern Med 1995; 237: 323-29.